This article was originally published in Start Up
Riccardo Pigliucci, former CEO of Life Sciences International PLC and past president and COO of Perkin Elmer Corp. thinks he has found a model that will serve the small companies' needs to build value, keep up with technological innovation and create large enough operations to make Big pharma feel comfortable in dealing with them. Discovery Partners International is a sort of holding company for drug discovery tool companies. It has made its first investments in combinatorial chemistry company Irori and chemical library provider ChemRx.
You may also be interested in...
Wound Solutions Ltd.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.
Where Private Medtech Investments Dollars Went in 2010
Overall in 2010, caution was the watchword for private investors, placing fewer dollars in fewer medtech deals compared to 2009. A total of $1.86 billion in private money was raised by medical device companies in 2010, a big drop from the $2.86 billion placed in the industry in 2009. Deal volume was down commensurately; there were 139 private medical device financings, compared to 207 in 2009. Investment dollars were apportioned, for the most part, in the usual fashion, with the largest proportion going into cardiovascular deals, followed by orthopedics. There were some surprises however, as a few categories, once avoided like the plaque, showed new investor interest.